Further studies are required to determine the molecular mechanisms by which the STAT3-blocked HCC vaccine promotes the crosstalk between STAT3 in tumor cells and immune cells, and relevant techniques before its use in clinical trials. This evidence concerns the gene STAT3 and hepatocellular carcinoma.